Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH ... fatty ...
NASH is a form of non-alcoholic fatty liver disease (NAFLD ... The THR agonist additionally reduced LDL-cholesterol, also linked to worsening NASH, cutting the biomarker by 12% and 16% at the ...
Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient. Secures Dedicated Fill/Finish Capacity for 100 Million Annua ...
In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and ...
In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and ...
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation ...
Hosted on MSN29d
Scotiabank Initiates Coverage of Viking Therapeutics (VKTX) with Sector Outperform RecommendationIn a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback